Replimune Group, Inc. (REPL)

Replimune Group Income Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Selling, General & Admin	59.81	59.81	50.55	38.77	23.2	17.44
Research & Development	174.96	174.96	126.53	79.55	56.75	38.76
Operating Expenses	234.77	234.77	177.08	118.31	79.96	56.2
Operating Income	-234.77	-234.77	-177.08	-118.31	-79.96	-56.2
Interest Expense / Income	6.66	6.66	4.16	2.22	3.06	1.92
Other Expense / Income	-26.05	-26.05	-7.24	-2.5	-2.15	-5.49
Pretax Income	-215.39	-215.39	-174	-118.04	-80.87	-52.63
Income Tax	0.41	0.41	0.29	0	0	0
Net Income	-215.79	-215.79	-174.28	-118.04	-80.87	-52.63
Shares Outstanding (Basic)	67	67	58	52	46	34
Shares Outstanding (Diluted)	67	67	58	52	46	34
Shares Change	14.36%	14.36%	11.49%	12.89%	34.99%	47.69%
EPS (Basic)	-3.24	-3.24	-2.99	-2.26	-1.75	-1.54
EPS (Diluted)	-3.24	-3.24	-2.99	-2.26	-1.75	-1.54
Free Cash Flow	-191.13	-191.13	-130.32	-84.52	-63.78	-67.09
Free Cash Flow Per Share	-2.87	-2.87	-2.24	-1.62	-1.38	-1.96
EBITDA	-206.07	-206.07	-167.39	-113.67	-76.1	-50.17
Depreciation & Amortization	2.66	2.66	2.45	2.15	1.71	0.53
EBIT	-208.73	-208.73	-169.84	-115.81	-77.81	-50.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).